Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (522)	5/27/1998 10:34:00 PM
From: SC	Read Replies (1) \| Respond to of 961

You missed it. Relenza mentioned in the news IS a treatment for flu. It says: "This follows the recent filing with regulatory authorities in Australia by Glaxo Wellcome Australia of Biota's anti-flu drug, RelenzaTM." "Sales of the diagnostic are expected to be limited prior to the availability of Relenza on the market. " "We expect that it will become an effective tool in quickly identifying patients with influenza, who can then be treated with the influenza therapy, Relenza, when it becomes available."